Health & Medicine | Dr Nikolai Sopko

New therapy offers hope for wound healing in severely burned patients

Serious burns are difficult to treat and can cause many complications. A common treatment for these injuries is a split-thickness skin graft, where a thin layer of healthy skin is taken from elsewhere on the patient’s body, meshed and transplanted onto the wound bed. Unfortunately, this type of treatment can lead to graft failure, contracture and scarring. PolarityTE, Inc., a biotechnology company in Salt Lake City, Utah, USA, has developed a revolutionary new treatment, SkinTE™, for burns and other skin defects, including chronic wounds and traumatic injuries. SkinTE™ has been proven to facilitate burn reconstruction and wound healing by regenerating fully functional new skin.

The human body has a remarkable ability to heal itself. Sometimes, though, the damage is just too severe, and even with the best medical care, the prognosis is poor. This has long been the case for patients with serious burns.

The graft is usually taken from a part of the body that heals well, such as the thighs or buttocks. The advantage of a split-thickness skin graft is that the donor site normally heals well within a few weeks, because the deeper part of the skin is left intact. However, there are some disadvantages. Only the outermost part of the skin is used, so the wound site does not recover its full function. Split-thickness skin grafts do not contain sweat or oil glands, or hair follicles. So, although split-thickness skin grafts can effectively function as a barrier, they may not aesthetically match the surrounding skin, for example in a colour or texture. There are also risks of graft failure, contraction of the donor skin and scarring.

Full-thickness skin grafts are also possible but leave a deeper wound that must be completely closed in order to heal and are limited by a 1:1 expansion ratio. For this reason, grafts must be relatively small and are not suitable for covering large wounds. Both full-thickness and split-thickness skin grafts have a failure rate of around 30%.

A NEW OPTION

PolarityTE has developed an innovative treatment, SkinTE™, for burns and other hard-to-treat skin defects, including wounds and traumatic injuries. PolarityTE is a biotechnology company that is focused on discovering, developing, and designing regenerative tissue products. SkinTE™ is a novel, first-of-its-kind treatment. The advanced technique has the potential to eliminate the unfavourable results of traditional treatments, like split-thickness skin grafts.

SkinTE™ is an autologous homologous skin construct (AHSC). “Autologous” because the tissue comes from the patient’s own body, and “homologous” because the donor graft will perform the same function in the area to which it is applied.

The company has established a seamless process for deploying SkinTE™. First, using a harvest kit provided by PolarityTE, the healthcare provider removes a small piece of healthy, full-thickness skin from the patient. Only a small sample of skin is needed to cover a large wound area, leading to minimal harvest-site morbidity. This differs from other methods which have been developed with a similar aim but use artifically manipulated homogeneous cells. The skin harvest is packed in a sterile, temperature-controlled container. The sample is returned to PolarityTE’s laboratory and the tissue is processed into AHSC or SkinTE™.

Once processed, SkinTE™ is returned within 48-72 hours to the healthcare provider in a harvest kit box. Once the affected area is cleaned and prepared, SkinTE™, contained within a syringe, is applied over the wound. The area is then dressed and treated skin to other types of skin grafts. Over time, SkinTE™ grows and expands to become full-thickness skin with a histology comparable to native skin. Throughout the process, healthcare professionals can communicate with a PolarityTE team of Clinical Science Managers. Treatment with SkinTE™ has been proven to regenerate skin with all layers, appendages and has even produced function such as sensation, sweat and pliability.

The development of SkinTE™ was inspired by recent research that shows that skin is more than just a barrier. Skin is a complex biological organ, playing major roles in cell signalling, metabolism and protein synthesis. As well as burns, SkinTE™ can be used to treat chronic wounds, including diabetic foot and venous stasis ulcers, acute traumatic wounds and amputation sites. It could also serve as a viable replacement of failed skin grafts, to replace scar tissue, and facilitate surgical reconstruction.

PROMISING RESULTS

SkinTE™ has already been used in a variety of clinical settings, ranging from intensive care units to wound care centres and outpatient clinics. PolarityTE is currently running multi-centred, controlled trials to compare SkinTE™ to current standards of care. Up to 16 centres in the US are expected to participate in each clinical centre. The workflow for clinicians is simple and easy to follow.

AHSC Workflow for clinic setting

The workflow for clinicians is simple and easy to follow.
SkinTE™ offers the potential for better treatment of extremely serious conditions and injuries.

A small sample of healthy skin was taken from the patient’s abdomen using the PolarityTE™ harvest kit. The sample was processed into SkinTE™ at PolarityTE and applied to the patient’s wounds two days after the small donor sample was taken. SkinTE™ was applied to the burns on the patient’s legs. At the same time, split-thickness skin grafts were used to treat the burns on her arms, using skin taken from the front of her torso.

By six weeks after SkinTE™ was deployed, full epithelialisation (the spread and anchoring of epithelial cells over the wound) on the patient’s legs had occurred. SkinTE™ was deployed, full epithelialisation (the spread and anchoring of epithelial cells over the wound) on the patient’s legs had occurred. This is the first step in the formation of new skin, where the new cells act as a barrier. By eight weeks, the patient was able to leave the hospital. At six months after SkinTE™ treatment, the regenerated skin on the patient’s legs had developed full function, as well as re-pigmentation and normalization. Unfortunately, the patient experienced contraction (when the graft shrinks) and irritation of the skin grafts applied to the wounds on her arms.

In this case, SkinTE™ was an effective treatment for a patient with extensive, full-thickness burns. SkinTE™ regenerated full-thickness skin, and development pigmentation, improving the appearance of the affected area and ultimately, improving the patient’s quality of life. Like most cases, only a single application of SkinTE™ was needed.

A BRIGHTER OUTLOOK

The novel technology behind SkinTE™ may offer better treatment of serious skin defects, injuries and conditions. Dr Nikolai Sopko and his research team believe that SkinTE™ has multiple benefits, including the ability to improve the function of new skin and the reduction in healing time, which can ultimately lead to shorter hospital stays and improved healthcare economics. SkinTE™ removes the need for large skin grafts to be taken from other parts of the body, leading to minimal harvest-site morbidity. The treatment also avoids some of the complications often seen with traditional split-thickness skin grafting. If PolarityTE’s clinical trials continue to produce encouraging results, SkinTE™ could become established as a standard treatment for patients with serious burns, chronic wounds, and other debilitating cutaneous conditions.

References


Collaborators

• David Armstrong DPM, MD, PhD
• Mark Granick MD
• Gerhard Sol Mundinger MD
• Anand Kumar MD

Personal Response

Could the technology behind SkinTE™ be used to develop treatments for other types of injury or chronic condition?

The technology behind SkinTE™ is incredibly powerful, in part, because it harnesses our body’s remarkable ability to heal itself. Although skin has a tremendous capacity for repair, it has not evolved to deal with difficult-to-treat injuries such as complex traumatic wounds that can occur in motor vehicle accidents or chronic wounds that can occur with ageing and exposure to chronic diseases. The technology helps optimise the body’s healing potential to close those challenging wounds, and we expect to see more and more encouraging clinical results in these settings. – Dr. Nikolai Sopko

Behind the Research

Nikolai Sopko, MD, PhD

Research Objectives

PolarityTE has developed products that enable regeneration of full-thickness skin with all layers and appendages, with recent research focusing on chronic wounds.

Detail

123 N Wright Brothers Drive
Salt Lake City
UT 84116
USA

Bio

Nikolai Sopko, MD, PhD is the Chief Scientific Officer and Medical Director at PolarityTE, Inc. – where he applies his passion for patient care and basic science research to develop novel regenerative therapeutics for clinically challenging diseases. He obtained his MD with honours from Case Western Reserve University and his PhD in stem cell biology at the Cleveland Clinic. He completed his surgical training at the Johns Hopkins James Buchanan Brady Urologic Institute as a Physician Scientist Scholar where he focused on regenerative reconstruction, tissue engineering, gene therapy, transplant modulation, and tumour biology. Dr Sopko has over 60 published peer-reviewed articles and book chapters and is an award-winning, accomplished speaker on regenerative medicine.

Personal Response

Could the technology behind SkinTE™ be used to develop treatments for other types of injury or chronic condition?

The technology behind SkinTE™ is incredibly powerful, in part, because it harnesses our body’s remarkable ability to heal itself. Although skin has a tremendous capacity for repair, it has not evolved to deal with difficult-to-treat injuries such as complex traumatic wounds that can occur in motor vehicle accidents or chronic wounds that can occur with ageing and exposure to chronic diseases. The technology helps optimise the body’s healing potential to close those challenging wounds, and we expect to see more and more encouraging clinical results in these settings. – Dr. Nikolai Sopko